#news #biotech BridgeBio spins out ultrarare genetic disease company after acquiring enzyme from Alexion

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: BridgeBio spins out ultrarare genetic disease company after acquiring enzyme from Alexion .Through an agreement with Alexion Pharmaceuticals, BridgeBio Pharma acquired a synthetic enzyme replacement therapy for an ultrarare, fatal genetic disease that causes seizures in infants. A new spinout, Origin Biosciences, will handle development.

from FierceBiotech: Biotech https://ift.tt/2sQhcxb